Therapy of gastric mucosa-associated lymphoid tissue lymphoma

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1263-1273

  Wöhrer, Stefan ^a   Troch, Marlene ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; Gastric MALT Lymphoma; Helicobacter pylori; Radiation

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FURAZOLIDONE; MITOXANTRONE; NITROIMIDAZOLE; ONCOPROTEIN; OXALIPLATIN; PREDNISONE; PROTEIN BCL 10; PROTEIN MALT1; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; RIFABUTIN; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COLONOSCOPY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; ENDOSCOPIC ECHOGRAPHY; GASTROSCOPY; GENE OVEREXPRESSION; GRANULOCYTOPENIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION CONTROL; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; REPEATED DRUG DOSE; REVIEW; STOMACH HEMORRHAGE; STOMACH MUCOSA; STOMACH PERFORATION; STOMACH SURGERY; TREATMENT OUTCOME; VISCERAL METASTASIS; MULTIMODALITY CANCER THERAPY; STOMACH TUMOR;

COMBINED MODALITY THERAPY; HELICOBACTER INFECTIONS; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; STOMACH NEOPLASMS;

EID: 34250893810     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1263     Document Type: Review

References (98)

1. HARRIS NL, JAFFE ES, DIEBOLD J et al.: The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod. Pathol. (2000) 13:193-207.
2. ISAACSON P, MOLLER-HERMELINK HY, PIRIS MA et al.: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL (Eds) IARC Press, Lyon (2001):157-160.
3. WOTHERSPOON AC, DOGLIONI C, DISS TC et al.: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet (1993) 342:575-577.
4. BRANDTZAEG P, FARSTAD IN, HARALDSEN G: Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today. (1999) 20:267-277.
5. DOGAN A, DU M, KOULIS A, BRISKIN MJ, ISAACSON PG: Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. Am. J. Pathol. (1997) 151:1361-1369.
6. BERLIN C, BERG EL, BRISKIN MJ et al. α4 β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell (1993) 74:185-195.
7. BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-I is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. (1997) 151:97-110.
8. DU MQ, PENG HZ, DOGAN A et al.: Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Blood (1997) 90:4071-4077.
9. DU MQ, XU CF, DISS TC et al.: Intestinal dissemination of gastric mucosa-associated lymphoid tissue lymphoma. Blood (1996) 88:4445-4451.
10. NEUBAUER A, THIEDE C, MORGNER A et al.: Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J. Natl. Cancer Inst. (1997) 89:1350-1355.
11. ROGGERO E, ZUCCA E, CAVALLI F: Gastric mucosa-associated lymphoid tissue lymphomas: more than a fascinating model. J. Natl. Cancer Inst. (1997) 89:1328-1330.
12. TRIEDE C, WUNDISCH T, NEUBAUER B et al.: Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: results of an ongoing multicenter trial. Recent Results Cancer Res. (2000) 156:125-133.
13. JANUNGER KG, HAFSTROM L, GLIMELIUS B: Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur. J. Surg. (2002) 168:597-608.
14. NAKAMURA T, NAKAMURA S, YONEZUMI M et al.: Helicobacter pylori and the t(11;18) (q21;q21) translocation in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn. J. Cancer Res. (2000) 91:301-309.
15. YEH KH, KUO SH, CHEN LT et al.: Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood (2005) 106:1037-1041.
16. ISAACSON P, WRIGHT DH: Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer (1984) 53:2515-2524.
17. SPENCER J, FINN T, ISAACSON PG: Human Peyer's patches: an immunohistochemical study. Gut (1986) 27:405-410.
18. WOTHERSPOON AC, ORTIZ-HIDALGO C, FALZON MR, ISAACSON PG: Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet (1991) 338:1175-1176.
19. ISAACSON PG, O'CONNOR NT, SPENCER J et al.: Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet (1985) 2:688-691.
20. HARRIS NL, JAFFE ES, STEIN H et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 84:1361-1392.
21. BERTONI F, ZUCCA E: Delving deeper into MALT lymphoma biology. J. Clin. Invest. (2006) 116:22-26.
22. DIERLAMM J, BAENS M, WLODARSKA I et al.: The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood (1999) 93:3601-3609.
23. STREUBEL B, LAMPRECHT A, DIERLAMM J et al.: T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood (2003) 101:2335-2339.
24. STREUBEL B, VINATZER U, LAMPRECHT A, RADERER M, CHOTT A: T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia (2005) 19:652-658.
25. WILLIS TG, JADAYEL DM, DU MQ et al.: Bcl10 is involved in t(1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell (1999) 96:35-45.
26. WOHRER S, ISAACSON PG, RADERER M: Complete regression of primary gastric plasmacytoma following Helicobacter pylori eradication. Ann. Hematol. (2004) 83:666.
27. YE H, DOGAN A, KARRAN L et al.: BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am. J. Pathol. (2000) 157:1147-1154.
28. FARINHA P, GASCOYNE RD: Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J. Clin. Oncol. (2005) 23:6370-6378.
29. YE H, LIU H, ATTYGALLE A et al.: Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood (2003) 102:1012-1018.
30. ROHATINER A, D'AMORE F, COIFFIER B et al.: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann. Oncol. (1994) 5:397-400.
31. MUSSHOFF K: [Clinical staging classification of non-Hodgkin's lymphomas (author's transl.)]. Strahlentherapie (1977) 153:218-221.
32. DRAGOSICS B, BAUER P, RADASZKIEWICZ T: Primary gastrointestinal non-Hodgkin's lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer (1985) 55:1060-1073.
33. RUSKONE-FOURMESTRAUX A, DRAGOSICS B, MORGNER A, WOTHERSPOON A, DE JONG D: Paris staging system for primary gastrointestinal lymphomas. Gut (2003) 52:912-913.
34. WOTHERSPOON AC, DOGLIONI C, ISAACSON PG: Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): a multifocal disease. Histopathology (1992) 20:29-34.
35. DU MQ DISS TC, DOGAN A et al.: Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa. J. Pathol. (2000) 192:488-493.
36. RADERER M, WOHRER S, STREUBEL B et al.: Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J. Clin. Oncol. (2006) 24:3136-3141.
37. WOHRER S, STREUBEL B, BARTSCH R, CHOTT A, RADERER M: Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin. Cancer Res. (2004) 10:7179-7181.
38. GISBERT JP, ABRAIRA V: Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am. J. Gastreenterol. (2006) 101:848-863.
39. MONTALBAN C, MANZANAL A, BOIXEDA D et al.: Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann. Oncol. (1997) 8(Suppl. 2):37-39.
40. SAVIO A, FRANZIN G, WOTHERSPOON AC et al.: Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood (1996) 87:1255-1260.
41. BAYERDORFFER E, NEUBAUER A, RUDOLPH B et al.: Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet (1995) 345:1591-1594.
42. ROGGERO E, ZUCCA E, PINOTTI G et al.: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann. Intern. Med. (1995) 122:767-769.
43. DU MQ, ISACCSON PG: Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol. (2002) 3:97-104.
44. FISCHBACH W, GOEBELER-KOLVE ME, DRAGOSICS B, GREINER A, STOLTE M: Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MAM) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut (2004) 53:34-37.
45. NAKAMURA S, MATSUMOTO T, SUEKANE H et al.: Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associatcd lymphoid tissue lymphoma with a reference to second-line treatment. Cancer (2005) 104:532-540.
46. WUNDISCH T, THIEDE C, MORGNER A et al.: Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J. Clin. Oncol. (2005) 23:8018-8024.
47. NAKAMURA S, MATSUMOTO T, SUEKANE H et al.: Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut (2001) 48:454-460.
48. RUSKONE-FOURMESTRAUX A, LAVERGNE A, AEGERTER PH et al.: Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment. Gut (2001) 48:297-303.
49. THIEDE C, WUNDISCH T, ALPEN B et al.: Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J. Clin. Oncol. (2001) 19:1600-1609.
50. STREUBEL B, HUBER D, WOHRER S, CHOTT A, RADERER M: Reverse transcription-PCR for t(11;18)(q21;q21) staging and monitoring in mucosa-associated lymphoid tissue lymphoma. Clin. Cancer Res. (2006) 12:6023-6028.
51. YE H, LIU H, RADERER M et al.: High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood (2003) 101:2547-2550.
52. RADERER M, STREUBEL B, WOHRER S, HAFNER M, CHOTT A: Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut (2006) 55:616-618.
53. MORGNER A, LEHN N, ANDERSEN LP et al.: Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterolog (2000) 118:821-828.
54. JONKERS D, GISBERTZ I, DE BRUINE A et al.: Helicobacter pylori and non-Helicobacter pylori bacterial flora in gastric mucosal and tumour specimens of patients with primary gastric lymphoma. Eur. J. Clin. Invest. (1997) 27:885-892.
55. OTRAKJI CL, ALBORES-SAAVEDRA J, MARTINEZ AJ: Gastric malignant lymphoma with superimposed amebiasis. Am. J. Gastroenterol. (1990) 85:72-75.
56. HOPTION CANN SA, VAN NETTEN JP, VAN NETTEN C: MALT lymphomas and Helicobacter pylori? Gut (2001) 48:283.
57. MORGNER A, LABENZ J, MIEHLKE S: Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin. Investig Drugs (2006) 15:995-1016.
58. EL-ZIMAITY HM, WOTHERSPOON A, DE JONG D: Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus. Blood Cells Mol. Dis. (2005) 34:6-16.
59. COPIE-BERGMAN C, GAULARD, P LAVERGNE-SLOVE A et al.: Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut (2003) 52:1656.
60. MONTALBAN C, SANTON A, REDONDO C et al.: Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. Ann. Oncol. (2005) 16:1539-1544.
61. RADERER M, STREUBEL B, WOEHRER S et al.: High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin. Cancer Res. (2005) 11:3349-3352.
62. WOHRER S, BARTSCH R, HEJNA M, DRACH J, RADERER M: Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy. Scand. J. Gastroenterol. (2005) 40:1222-1225.
63. HAMMEL P, HAIOUN C, CHAUMETTE MT et al.: Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J. Clin. Oncol. (1995) 13:2524-2529.
64. LEVY M, COPIE-BERGMAN C, GAMEIRO C et al.: Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J. Clin. Oncol. (2005) 23:5061-5066.
65. GREINER A, KNORR C, QIN Y et al.: Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am. J. Pathol. (1997) 150:1583-1593.
66. HUSSELL T, ISAACSON PG, CRABTREE JE, SPENCER J: The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet (1993) 342:571-574.
67. HUSSELL T, ISAACSON PG, CRABTREE JE, SPENCER J: Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J. Pathol. (1996) 178:122-127.
68. HUSSELL T, ISAACSON PG, SPENCER J: Proliferation and differentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro. J. Pathol. (1993) 169:221-227.
69. ISAACSON PG: Gastric MALT lymphoma: from concept to cure. Ann. Oncol. (1999) 10:637-645.
70. JAGER G, NEUMEISTER P, BREZINSCHEK R et al.: Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J. Clin. Oncol. (2002) 20:3872-3877.
71. JAGER G, NEUMEISTER P, QUEHENBERGER F, WOHRER S, LINKESCH W, RADERER M: Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann. Oncol. (2006) 17(11):1722-1723
72. GERMANN N, BRIENZA S, ROTARSKI M et al.: Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann. Oncol. (1999) 10:351-354.
73. OKI Y, MCLAUGHLIN P, PRO B et al.: Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer (2005) 104:781-787.
74. RADERER M, WOHRER S, BARTSCH R et al.: Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J. Clin. Oncol. (2005) 23:8442-8446.
75. CHAU I, WEBB A, CUNNINGHAM D et al.: An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br. J. Haematol. (2001) 115:786-792.
76. MACHOVER D, DELMAS-MARSALET B, MISRA SC et al.: Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann. Oncol. (2001) 12:1439-1443.
77. AVILES A, NAMBO MJ, NERI N, TALAVERA A, CLETO S: Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med. Oncol. (2005) 22:57-62.
78. WOHRER S, DRACH J, HEJNA M et al.: Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann. Oncol. (2003) 14:1758-1761.
79. RADERER M, JAGER G, BRUGGER S et al.: Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology (2003) 65:306-310.
80. CONCONI A, MARTINELLI G, THIEBLEMONT C et al.: Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 102:2741-2745.
81. MARTINELLI G, LASZLO D, FERRERI AJ et al.: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J. Clin. Oncol. (2005) 23:1979-1983.
82. RADERER M, WOHRER S, STREUBEL B et al.: Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology (2007) 70:411-417.
83. BURGERS JM, TAAL BG, VAN HEERDE P et al.: Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach. Radiother Oncol (1988) 11:319-326.
84. SCHECHTER NR, PORTLOCK CS, YAHALOM J: Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J. Clin. Oncol. (1998) 16:1916-1921.
85. TSANG RW, GOSPODAROWICZ MK, PINTILIE M et al.: Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J. Clin. Oncol. (2003) 21:4157-4164.
86. KOCH P, PROBST A, BERDEL WE et al.: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J. Clin. Oncol. (2005) 23:7050-7059.
87. SCHECHTER NR, YAHALOM J: Low-grade MALT lymphoma of the stomach: a review of treatment options. Int. J. Radiat. Oncol. Biol. Phys. (2000) 46:1093-103.
88. MITTAL B, WASSERMAN TH, GRIFFITH RC: Non-Hodgkin's lymphoma of the stomach. Am. J. Gastroenterol. (1983) 78:780-787.
89. MAOR MH, NORTH LB, CABANILLAS FF, AMES AL, HESS MA, COX JD: Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma. Int. J. Radiat. Oncol. Biol. Phys. (1998) 41:647-650.
90. VERHEIJ M, DEWIT LG, VALDES OLMOS RA, ARISZ L: Evidence for a renovascular component in hypertensive patients with late radiation nephropathy. Int. J. Radiat. Oncol. Biol. Phys. (1994) 30:677-683.
91. ETTINGER DS, CARTER D: Gastric carcinoma 16 years after gastric lymphoma irradiation. Am. J. Gastroenterol. (1977) 68:485-488.
92. SHANI A, SCHUTT AJ, WEILAND LH: Primary gastric malignant lymphoma followed by gastric adenocarcinoma: report of 4 cases and review of the literature. Cancer (1978) 42:2039-2044.
93. BARON BW, BITTER MA, BARON JM, BOSTWICK DG: Gastric adenocarcinoma after gastric lymphoma. Cancer (1987) 60:1876-1882.
94. GHAHREMANI GG, FISHER MR: Lymphoma of the stomach following gastric surgery for benign peptic ulcers. Gastrointest. Radiol. (1983) 8:213-217.
95. DE KOSTER E, BUSET M, FERNANDES E, DELTENRE M: Helicobacter pylori: the link with gastric cancer. Eur. J. Cancer Prev. (1994) 3 :247-257.
96. GRIFFITHS AP, WYATT J, JACK AS, DIXON MF: Lymphocytic gastritis, gastric adenocarcinoma, and primary gastric lymphoma. Clin Pathol. (1994) 47:1123-1124.
97. GRÜNBERGER B, WOHRER S, STREUBEL B, FORMANEK M et al.: Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J. Clin. Oncol. (2006) 24(9):1370-1375.
98. COIFFIER B: First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin. Adv. Hematol. Oncol. (2005) 3:484-491, 505.